Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK189254 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Arm A1 | EXPERIMENTAL | In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2. |
| Treatment Arm A2 | EXPERIMENTAL | In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2. |
| Treatment Arm B1 | EXPERIMENTAL | In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2. |
| Treatment Arm B2 | EXPERIMENTAL | In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2. |
| Name | Type | Description |
|---|---|---|
| Duloxetine | DRUG | Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B. |
| GSK189254 | DRUG | Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A. |
| GSK189254 Placebo | DRUG | Subjects will receive Placebo matching GSK189254 for 3 weeks in each period. |
| Duloxetine Placebo | DRUG | Subjects will receive Placebo matching Duloxetine for 3 weeks in each period. |
Inclusion Criteria: * He/she is a healthy subject. * Women of child bearing potential must have a negative pregnancy test at screening and have undergone, or confirm regular use of one of the following: Female sterilisation Sterilisation of male partner Practising a clinically accepted method of c...
GSK189254 is an investigational small molecule being developed for hyperalgesia, an increased sensitivity to pain. It is being studied in the electrical hyperalgesia model, which is a pain model used in clinical research. The drug is in Phase 1 clinical development and is not yet approved for any use.
GSK189254 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of GSK189254 in healthy volunteers.
GSK189254 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a Phase 1 trial that has been completed, and it remains in the early stages of clinical research.
GSK189254 has been studied in one clinical trial with the identifier NCT00387413. This Phase 1 trial, titled 'A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers,' was conducted in the United Kingdom and enrolled 40 participants. The trial has been completed.
No, GSK189254 is not the same as duloxetine. GSK189254 is an investigational small molecule being developed by GSK plc, while duloxetine is an established medication. In the clinical trial NCT00387413, both GSK189254 and duloxetine were studied in the electrical hyperalgesia model, but they are distinct drugs.